Pharmacoproteomic study of the natural product Ebenfuran III in DU-145 prostate cancer cells: The quantitative and temporal interrogation of chemically induced cell death at the protein level

Journal of Proteome Research

Volumn 12, Issue 4, 2013, Pages 1591-1603

  Roumeliotis, Theodoros I ^a   Halabalaki, Maria ^b,c   Alexi, Xanthippi ^d   Ankrett, Dyan ^e   Giannopoulou, Eugenia G ^f   Skaltsounis, Alexios Leandros ^b   Sayan, Berna S ^a   Alexis, Michael N ^d   Townsend, Paul A ^g   Garbis, Spiros D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d INSTITUTE OF BIOLOGY   (Greece)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

DU 145 prostate cancer cells; Ebenfuran III

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; CALPAIN 1; EBENFURAN III; NATURAL PRODUCT; PROTEINASE ACTIVATED RECEPTOR 4; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; IMMUNODETECTION; ION EXCHANGE CHROMATOGRAPHY; LEGUME; MOLECULAR WEIGHT; ONOBRYCHIS EBENOIDES; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SECRETION; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS REGULATORY PROTEINS; BENZOFURANS; CALPAIN; CELL DEATH; CELL LINE, TUMOR; CHROMATOGRAPHY, REVERSE-PHASE; CLUSTER ANALYSIS; HUMANS; MALE; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; PROSTATIC NEOPLASMS; PROTEINS; RAB GTP-BINDING PROTEINS; RESORCINOLS; TANDEM MASS SPECTROMETRY;

FABACEAE; ONOBRYCHIS EBENOIDES;

EID: 84875926034     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr300968q     Document Type: Article

References (84)

1. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation Cell 2011, 144 (5) 646-74
2. David, A. R.; Zimmerman, M. R. Cancer: an old disease, a new disease or something in between? Nat. Rev. Cancer 2010, 10 (10) 728-33
3. Eheman, C.; Henley, S. J.; Ballard-Barbash, R.; Jacobs, E. J.; Schymura, M. J.; Noone, A. M.; Pan, L.; Anderson, R. N.; Fulton, J. E.; Kohler, B. A.; Jemal, A.; Ward, E.; Plescia, M.; Ries, L. A.; Edwards, B. K. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity Cancer 2012, 118 (9) 2338-66
4. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J. Clin. 2011, 61 (4) 212-36
5. Otto, S. J.; van Leeuwen, P. J.; Hoekstra, J. W.; Merckelbach, J. W.; Blom, J. H.; Schroder, F. H.; Roobol, M. J.; de Koning, H. J. Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial? Eur. J. Cancer 2010, 46 (17) 3061-7
6. Otto, S. J.; Moss, S. M.; Maattanen, L.; Roobol, M.; Zappa, M.; Nelen, V.; Kwiatkowski, M.; Villers, A.; Hugosson, J.; Sanchez, A. B.; de Koning, H. J. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer Eur. J. Cancer 2010, 46 (17) 3053-60
7. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012 CA Cancer J. Clin. 2012, 62 (1) 10-29
8. Tendulkar, R. D.; Reddy, C. A.; Stephans, K. L.; Ciezki, J. P.; Klein, E. A.; Mahadevan, A.; Kupelian, P. A. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy Int. J. Radiat. Oncol. Biol. Phys. 2012, 82 (4) 1397-404
9. Suardi, N.; Ficarra, V.; Willemsen, P.; De Wil, P.; Gallina, A.; De Naeyer, G.; Schatteman, P.; Montorsi, F.; Carpentier, P.; Mottrie, A. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years Urology 2012, 79 (1) 133-8
10. Boorjian, S. A.; Eastham, J. A.; Graefen, M.; Guillonneau, B.; Karnes, R. J.; Moul, J. W.; Schaeffer, E. M.; Stief, C.; Zorn, K. C. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes Eur. Urol. 2012, 61 (4) 664-75
11. Klein, E. A.; Thompson, I. M. Chemoprevention of prostate cancer: an updated view World J. Urol. 2012, 30 (2) 189-94
12. Thapa, D.; Ghosh, R. Antioxidants for prostate cancer chemoprevention: challenges and opportunities Biochem. Pharmacol. 2012, 83 (10) 1319-30
13. Kumar, N.; Crocker, T.; Smith, T.; Pow-Sang, J.; Spiess, P. E.; Connors, S.; Chornukur, G.; Dickinson, S. I.; Bai, W.; Williams, C. R.; Salup, R.; Fu, W. Prostate cancer chemoprevention targeting high risk populations: model for trial design and outcome measures J. Cancer Sci. Ther. 2012, 2011, S3
14. Sporn, M. B. New agents for chemoprevention of prostate cancer Eur. Urol. 1999, 35 (5-6) 420-3
15. Sporn, M. B.; Liby, K. T. Cancer chemoprevention: scientific promise, clinical uncertainty Nat. Clin. Pract. Oncol. 2005, 2 (10) 518-25
16. Miyanaga, N.; Akaza, H.; Hinotsu, S.; Fujioka, T.; Naito, S.; Namiki, M.; Takahashi, S.; Hirao, Y.; Horie, S.; Tsukamoto, T.; Mori, M.; Tsuji, H. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen Cancer Sci. 2012, 103 (1) 125-30
17. Araldi, E. M.; Dell'aica, I.; Sogno, I.; Lorusso, G.; Garbisa, S.; Albini, A. Natural and synthetic agents targeting inflammation and angiogenesis for chemoprevention of prostate cancer Curr. Cancer Drug Targets 2008, 8 (2) 146-55
18. Siddiqui, I. A.; Afaq, F.; Adhami, V. M.; Mukhtar, H. Prevention of prostate cancer through custom tailoring of chemopreventive regimen Chem. Biol. Interact. 2008, 171 (2) 122-32
19. Sporn, M. B.; Suh, N. Chemoprevention of cancer Carcinogenesis 2000, 21 (3) 525-30
20. Sporn, M. B.; Suh, N. Chemoprevention: an essential approach to controlling cancer Nat. Rev. Cancer 2002, 2 (7) 537-43
21. Thompson, I. M. Chemoprevention of prostate cancer: lessons learned BJU Int. 2007, 100 (Suppl 2) 15-7
22. Violette, P. D.; Saad, F. Chemoprevention of prostate cancer: myths and realities J. Am. Board Fam. Med. 2012, 25 (1) 111-9
23. Lippman, S. M.; Levin, B. Cancer prevention: strong science and real medicine J. Clin. Oncol. 2005, 23 (2) 249-53
24. Lippman, S. M.; Goodman, P. J.; Klein, E. A.; Parnes, H. L.; Thompson, I. M., Jr.; Kristal, A. R.; Santella, R. M.; Probstfield, J. L.; Moinpour, C. M.; Albanes, D.; Taylor, P. R.; Minasian, L. M.; Hoque, A.; Thomas, S. M.; Crowley, J. J.; Gaziano, J. M.; Stanford, J. L.; Cook, E. D.; Fleshner, N. E.; Lieber, M. M.; Walther, P. J.; Khuri, F. R.; Karp, D. D.; Schwartz, G. G.; Ford, L. G.; Coltman, C. A., Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT) J. Natl. Cancer Inst. 2005, 97 (2) 94-102
25. Wu, X.; Lippman, S. M. An intermittent approach for cancer chemoprevention Nat Rev Cancer 2011, 11 (12) 879-85
26. Klein, E. A.; Thompson, I. M., Jr.; Tangen, C. M.; Crowley, J. J.; Lucia, M. S.; Goodman, P. J.; Minasian, L. M.; Ford, L. G.; Parnes, H. L.; Gaziano, J. M.; Karp, D. D.; Lieber, M. M.; Walther, P. J.; Klotz, L.; Parsons, J. K.; Chin, J. L.; Darke, A. K.; Lippman, S. M.; Goodman, G. E.; Meyskens, F. L., Jr.; Baker, L. H. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 2011, 306 (14) 1549-56
27. Katsanou, E. S.; Halabalaki, M.; Aligiannis, N.; Mitakou, S.; Skaltsounis, A. L.; Alexi, X.; Pratsinis, H.; Alexis, M. N. Cytotoxic effects of 2-arylbenzofuran phytoestrogens on human cancer cells: modulation by adrenal and gonadal steroids J. Steroid Biochem. Mol. Biol. 2007, 104 (3-5) 228-36
28. Papoutsi, Z.; Kassi, E.; Papaevangeliou, D.; Pratsinis, H.; Zoumpourlis, V.; Halabalaki, M.; Mitakou, S.; Kalofoutis, A.; Moutsatsou, P. Plant 2-arylobenzofurans demonstrate a selective estrogen receptor modulator profile Steroids 2004, 69 (11-12) 727-34
29. Halabalaki, M.; Aligiannis, N.; Papoutsi, Z.; Mitakou, S.; Moutsatsou, P.; Sekeris, C.; Skaltsounis, A. L. Three new arylobenzofurans from Onobrychis ebenoides and evaluation of their binding affinity for the estrogen receptor J. Nat. Prod. 2000, 63 (12) 1672-4
30. Halabalaki, M.; Alexi, X.; Aligiannis, N.; Alexis, M. N.; Skaltsounis, A. L. Ebenfurans IV-VIII from Onobrychis ebenoides: evidence that C-prenylation is the key determinant of the cytotoxicity of 3-formyl-2-arylbenzofurans J. Nat. Prod. 2008, 71 (11) 1934-7
31. Kocher, T.; Superti-Furga, G. Mass spectrometry-based functional proteomics: from molecular machines to protein networks Nat. Methods 2007, 4 (10) 807-15
32. Waters, K. M.; Liu, T.; Quesenberry, R. D.; Willse, A. R.; Bandyopadhyay, S.; Kathmann, L. E.; Weber, T. J.; Smith, R. D.; Wiley, H. S.; Thrall, B. D. Network analysis of epidermal growth factor signaling using integrated genomic, proteomic and phosphorylation data PLoS One 2012, 7 (3) e34515
33. Witzmann, F. A.; Grant, R. A. Pharmacoproteomics in drug development Pharmacogenomics J. 2003, 3 (2) 69-76
34. Chapal, N.; Molina, L.; Molina, F.; Laplanche, M.; Pau, B.; Petit, P. Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer Fundam. Clin. Pharmacol. 2004, 18 (4) 413-22
35. Singh, O. V.; Vij, N.; Mogayzel, P. J., Jr.; Jozwik, C.; Pollard, H. B.; Zeitlin, P. L. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells J. Proteome Res. 2006, 5 (3) 562-71
36. Wang, Y.; Dai, Z.; Sadee, W.; Hancock, W. S. A pharmacoproteomics study of the cancer cell line EKVX using capillary-LC/MS/MS Mol. Pharm. 2006, 3 (5) 566-78
37. Arrell, D. K.; Niederlander, N. J.; Perez-Terzic, C.; Chung, S.; Behfar, A.; Terzic, A. Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics Clin. Pharmacol. Ther. 2007, 82 (3) 316-9
38. D'Alessandro, A.; Zolla, L. Pharmacoproteomics: a chess game on a protein field Drug Discov. Today 2010, 15 (23-24) 1015-23
39. Wang, L. S.; Xia, L.; Shen, S. M.; Zheng, Y.; Yu, Y.; Chen, G. Q. Dissecting cell death with proteomic scalpels Proteomics 2012, 12 (4-5) 597-606
40. Sharma, S. V.; Haber, D. A.; Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents Nat. Rev. Cancer 2010, 10 (4) 241-53
41. Carlson, S. M.; White, F. M. Using small molecules and chemical genetics to interrogate signaling networks ACS Chem. Biol. 2011, 6 (1) 75-85
42. Castoreno, A. B.; Eggert, U. S. Small molecule probes of cellular pathways and networks ACS Chem. Biol. 2011, 6 (1) 86-94
43. Lin, B.; White, J. T.; Lu, W.; Xie, T.; Utleg, A. G.; Yan, X.; Yi, E. C.; Shannon, P.; Khrebtukova, I.; Lange, P. H.; Goodlett, D. R.; Zhou, D.; Vasicek, T. J.; Hood, L. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease Cancer Res. 2005, 65 (8) 3081-91
44. Schwanhausser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global quantification of mammalian gene expression control Nature 2011, 473 (7347) 337-42
45. McCarty, M. F. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy Integr. Cancer Ther. 2004, 3 (4) 349-80
46. Hess, S. The emerging field of chemo- and pharmacoproteomics Proteomics Clin. Appl. 2013, 7 (1-2) 171-80
47. Sung, F. L.; Pang, R. T.; Ma, B. B.; Lee, M. M.; Chow, S. M.; Poon, T. C.; Chan, A. T. Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma J. Proteome Res. 2006, 5 (12) 3260-7
48. Wulfkuhle, J. D.; Edmiston, K. H.; Liotta, L. A.; Petricoin, E. F., 3rd Technology insight: pharmacoproteomics for cancer - promises of patient-tailored medicine using protein microarrays Nat. Clin. Pract. Oncol. 2006, 3 (5) 256-68
49. Jain, K. K. Role of pharmacoproteomics in the development of personalized medicine Pharmacogenomics 2004, 5 (3) 331-6
50. Butler, G. S.; Dean, R. A.; Tam, E. M.; Overall, C. M. Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding Mol. Cell. Biol. 2008, 28 (15) 4896-914
51. Garbis, S.; Lubec, G.; Fountoulakis, M. Limitations of current proteomics technologies J. Chromatogr., A 2005, 1077 (1) 1-18
52. Garbis, S. D.; Tyritzis, S. I.; Roumeliotis, T.; Zerefos, P.; Giannopoulou, E. G.; Vlahou, A.; Kossida, S.; Diaz, J.; Vourekas, S.; Tamvakopoulos, C.; Pavlakis, K.; Sanoudou, D.; Constantinides, C. A. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry J. Proteome Res. 2008, 7 (8) 3146-58
53. Bouchal, P.; Roumeliotis, T.; Hrstka, R.; Nenutil, R.; Vojtesek, B.; Garbis, S. D. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis J. Proteome Res. 2009, 8 (1) 362-73
54. Garbis, S. D.; Roumeliotis, T. I.; Tyritzis, S. I.; Zorpas, K. M.; Pavlakis, K.; Constantinides, C. A. A novel multidimensional protein identification technology approach combining protein size exclusion prefractionation, peptide zwitterion-ion hydrophilic interaction chromatography, and nano-ultraperformance RP chromatography/nESI-MS2 for the in-depth analysis of the serum proteome and phosphoproteome: application to clinical sera derived from humans with benign prostate hyperplasia Anal. Chem. 2011, 83 (3) 708-18
55. Shilov, I. V.; Seymour, S. L.; Patel, A. A.; Loboda, A.; Tang, W. H.; Keating, S. P.; Hunter, C. L.; Nuwaysir, L. M.; Schaeffer, D. A. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra Mol. Cell. Proteomics 2007, 6 (9) 1638-55
56. Tang, W. H.; Shilov, I. V.; Seymour, S. L. Nonlinear fitting method for determining local false discovery rates from decoy database searches J. Proteome Res. 2008, 7 (9) 3661-7
57. Zhan, X.; Desiderio, D. M. Signaling pathway networks mined from human pituitary adenoma proteomics data BMC Med. Genomics 2010, 3, 13
58. Kulkarni, Y. M.; Suarez, V.; Klinke, D. J., 2nd Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling BMC Cancer 2010, 10, 291
59. Albini, A.; Sporn, M. B. The tumour microenvironment as a target for chemoprevention Nat. Rev. Cancer 2007, 7 (2) 139-47
60. Mueller, M. M.; Fusenig, N. E. Friends or foes-bipolar effects of the tumour stroma in cancer Nat. Rev. Cancer 2004, 4 (11) 839-49
61. Hainaut, P.; Plymoth, A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy Curr. Opin. Oncol. 2013, 25 (1) 50-1
62. Hanash, S. M.; Pitteri, S. J.; Faca, V. M. Mining the plasma proteome for cancer biomarkers Nature 2008, 452 (7187) 571-9
63. Sawyers, C. L. The cancer biomarker problem Nature 2008, 452 (7187) 548-52
64. Chen, J. R.; Plotkin, L. I.; Aguirre, J. I.; Han, L.; Jilka, R. L.; Kousteni, S.; Bellido, T.; Manolagas, S. C. Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens J. Biol. Chem. 2005, 280 (6) 4632-8
65. Kairouz-Wahbe, R.; Biliran, H.; Luo, X.; Khor, I.; Wankell, M.; Besch-Williford, C.; Pascual, J.; Oshima, R.; Ruoslahti, E. Anoikis effector Bit1 negatively regulates Erk activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (5) 1528-32
66. Polster, B. M.; Basanez, G.; Etxebarria, A.; Hardwick, J. M.; Nicholls, D. G. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria J. Biol. Chem. 2005, 280 (8) 6447-54
67. Leloup, L.; Wells, A. Calpains as potential anti-cancer targets Expert Opin. Ther. Targets 2011, 15 (3) 309-23
68. Storr, S. J.; Carragher, N. O.; Frame, M. C.; Parr, T.; Martin, S. G. The calpain system and cancer Nat. Rev. Cancer 2011, 11 (5) 364-74
69. Chakraborty, M.; Qiu, S. G.; Vasudevan, K. M.; Rangnekar, V. M. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression Cancer Res. 2001, 61 (19) 7255-63
70. Goswami, A.; Ranganathan, P.; Rangnekar, V. M. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target Cancer Res. 2006, 66 (6) 2889-92
71. Burikhanov, R.; Zhao, Y.; Goswami, A.; Qiu, S.; Schwarze, S. R.; Rangnekar, V. M. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis Cell 2009, 138 (2) 377-88
72. Ng, F. W.; Nguyen, M.; Kwan, T.; Branton, P. E.; Nicholson, D. W.; Cromlish, J. A.; Shore, G. C. p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum J. Cell Biol. 1997, 139 (2) 327-38
73. Breckenridge, D. G.; Stojanovic, M.; Marcellus, R. C.; Shore, G. C. Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol J. Cell Biol. 2003, 160 (7) 1115-27
74. Schroder, M.; Kaufman, R. J. ER stress and the unfolded protein response Mutat. Res. 2005, 569 (1-2) 29-63
75. Edinger, A. L.; Cinalli, R. M.; Thompson, C. B. Rab7 prevents growth factor-independent survival by inhibiting cell-autonomous nutrient transporter expression Dev. Cell 2003, 5 (4) 571-82
76. He, Q.; Lee, D. I.; Rong, R.; Yu, M.; Luo, X.; Klein, M.; El-Deiry, W. S.; Huang, Y.; Hussain, A.; Sheikh, M. S. Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway Oncogene 2002, 21 (17) 2623-33
77. Yamaguchi, H.; Wang, H. G. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells J. Biol. Chem. 2004, 279 (44) 45495-502
78. Sorkin, A.; von Zastrow, M. Endocytosis and signalling: intertwining molecular networks Nat. Rev. Mol. Cell Biol. 2009, 10 (9) 609-22
79. Snider, M. D. A role for rab7 GTPase in growth factor-regulated cell nutrition and apoptosis Mol. Cell 2003, 12 (4) 796-7
80. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease Cell 2008, 132 (1) 27-42
81. Maiuri, M. C.; Zalckvar, E.; Kimchi, A.; Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis Nat. Rev. Mol. Cell Biol. 2007, 8 (9) 741-52
82. Powers, M. V.; Workman, P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocr. Relat. Cancer 2006, 13 (Suppl 1) S125-35
83. Hartson, S. D.; Matts, R. L. Approaches for defining the Hsp90-dependent proteome Biochim. Biophys. Acta 2012, 1823 (3) 656-67
84. da Silva, V. C.; Ramos, C. H. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics J. Proteomics 2012, 75 (10) 2790-802